{
  "guideline": {
    "id": "PA166182722",
    "name": "Annotation of FDA Label for erdafitinib and CYP2C9",
    "source": "FDA",
    "version": 14,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182722",
    "relatedChemicals": [
      {
        "id": "PA166182720",
        "name": "erdafitinib",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312702",
      "name": "Recommendation Annotation PA166312702",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182720",
          "name": "erdafitinib",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452219001,
        "html": "<p>&quot;Erdafitinib plasma concentrations were predicted to be higher in patients with the CYP2C9*3/*3 genotype. Monitor for increased adverse reactions in patients who are known or suspected to have CYP2C9*3/*3 genotype.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2C9": {
          "*3": 2.0
        }
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product BALVERSA (Erdafitinib), NDA212018, Janssen Products LP",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212018"
    }
  ],
  "version": "2024-02-29-20-19"
}